RecruitingNCT06287749

French Assessment of MRD by Liquid Biopsies in PDAC Patients (FRENCH.MRD.PDAC)

French Assessment of Minimal Residual Disease by Liquid Biopsies in Pancreatic Ductal Adenocarcinoma Patients

Sponsor

University Hospital, Montpellier

Enrollment

37 participants

Start Date

Mar 1, 2024

Study Type

OBSERVATIONAL

Conditions

Pancreatic Ductal Adenocarcinoma Minimal Residual Disease ctDNA Pancreatic Cancer Resectable Liquid Biopsy

Summary

The overall objective of this GUIDE.MRD consortium is to confirm that ctDNA detected after curative intended treatment for PDAC is a marker of residual disease and for risk-of-recurrence, and applicable in clinical practice. Primary objective To confirm that ctDNA analyses performed after PDAC treatment can identify patients with a high risk-of-recurrence. Specifically, the investigators want to determine the association between disease-free survival (DFS) and ctDNA detection status after 1. curative-intended surgery and 2. adjuvant chemotherapy. FRENCH.MRD.PDAC is the French study of the european GUIDE.MRD project

Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This study is investigating whether liquid biopsy blood tests (which detect traces of cancer DNA in the blood) can detect residual cancer after surgery for pancreatic cancer, to guide treatment decisions. **You may be eligible if...** - You have been diagnosed with pancreatic ductal adenocarcinoma (the most common type of pancreatic cancer) - You are 18 or older - You are scheduled for surgery with the goal of curing the cancer **You may NOT be eligible if...** - Your pancreatic cancer is hereditary (genetic) - Your cancer has spread to distant organs (metastases) - You have had another cancer within the past 3 years (excluding certain skin cancers) - You are pregnant or nursing - You are not covered by health insurance Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.